Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders

被引：14

作者：

Yoon, David S. ^{[1
]}

Wu, Shung C. ^{[1
]}

Seethala, Ramakrishna ^{[2
]}

Golla, Rajasree ^{[2
]}

Nayeem, Akbar ^{[3
]}

Everlof, John G. ^{[4
]}

Gordon, David A. ^{[5
]}

Hamann, Lawrence G. ^{[1
]}

Robl, Jeffrey A. ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Res & Dev, Dept Chem, Princeton, NJ 08543 USA

[2] Bristol Myers Squibb Co, Res & Dev, Lead Evaluat, Princeton, NJ 08543 USA

[3] Bristol Myers Squibb Co, Res & Dev, CADD, Princeton, NJ 08543 USA

[4] Bristol Myers Squibb Co, Res & Dev, PCO Discovery Pharmaceut, Princeton, NJ 08543 USA

[5] Bristol Myers Squibb Co, Res & Dev, Dept Biol, Princeton, NJ 08543 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 21期

关键词：

11-Beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1); Enzyme inhibitor; Pyridyl sulfonamide; Type-2; diabetes; SELECTIVE INHIBITORS; VISCERAL OBESITY; POTENT; HYPERGLYCEMIA; DESIGN; MODEL; MICE;

D O I：

10.1016/j.bmcl.2014.09.012

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A previous disclosure from this lab highlighted the discovery of pyridyl amides as potent 11 beta-HSD1 inhibitors. In order to build additional novelty and polarity into this chemotype, replacement of the hydrogen-bonding carbonyl (CO) pharmacophore with the bioisosteric sulfonyl (SO2) group was examined. Despite initial comparisons suggesting the corresponding sulfonamides exhibited weaker activity versus their carbonyl counterparts, further optimization was performed in an effort to identify various potent and unique leads for the program. Judicious incorporation of polar moieties resulted in the identification of compounds with enhanced potency and lipophilicity profiles, resulting in leads with superior aqueous solubility and liver microsomal stability. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：5045 / 5049

页数：5

共 50 条

[21] Discovery of novel, potent benzamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model
Julian, Lisa D.
Wang, Zhulun
Bostick, Tracy
Caille, Seb
Choi, Rebekah
DeGraffenreid, Michael
Di, Yongmei
He, Xiao
Hungate, Randall W.
Jaen, Juan C.
Liu, Jinsong
Monshouwer, Mario
McMinn, Dustin
Rew, Yosup
Sudom, Athena
Sun, Daqing
Tu, Hua
Ursu, Stefania
Walker, Nigel
Yan, Xuelei
Ye, Qiuping
Powers, Jay P.
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (13) : 3953 - 3960
[22] 11β- Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) mediates insulin resistance through JNK activation in adipocytes
Peng, Kesong
Pan, Yong
Li, Jieli
Khan, Zia
Fan, Mendi
Yin, Haimin
Tong, Chao
Zhao, Yunjie
Liang, Guang
Zheng, Chao
SCIENTIFIC REPORTS, 2016, 6
[23] 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Mediates Insulin Resistance through JNK Activation in Adipocytes
Zheng, Chao
Liang, Guang
DIABETES, 2016, 65 : A442 - A442
[24] 11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) mediates insulin resistance through JNK activation in adipocytes
Kesong Peng
Yong Pan
Jieli Li
Zia Khan
Mendi Fan
Haimin Yin
Chao Tong
Yunjie Zhao
Guang Liang
Chao Zheng
Scientific Reports, 6
[25] Possible pathogenetic role of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) gene polymorphisms in arterial hypertension
Morales, Mauricio A.
Carvajal, Cristian A.
Ortiz, Eugenia
Mosso, Lorena M.
Artigas, Rocio A.
Owen, Gareth I.
Fardella, Carlos E.
REVISTA MEDICA DE CHILE, 2008, 136 (06) : 701 - 710
[26] IMMUNOLOCALIZATION OF NAD-DEPENDENT 11-BETA-HYDROXYSTEROID DEHYDROGENASE (HSD)
KYOSSEV, Z
WALKER, P
REEVES, WB
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 739 - 739
[27] ENDOGENOUS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE IN HYPERTENSION
WALKER, BR
AGGARWAL, I
STEWART, PM
PADFIELD, PL
EDWARDS, CRW
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (02): : 529 - 533
[28] Radiosynthesis and evaluation of an 11-beta hydroxysteroid dehydrogenase-1 (11β-HSD1) PET ligand in rhesus monkey
Li Wenping
Joshi, Aniket
Zeng Zhizhen
O'Malley, Stacey S.
Miller, Patricia J.
Riffel, Kerry
Purcell, Mona L.
Gantert, Liza T.
Eng, Waisi
Krause, Stephen
Williams, Mangay
Balkovec, James M.
Waddell, Sherman T.
Cook, Jacquelynn J.
Hamill, Terence G.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2011, 54 : S293 - S293
[29] 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome
Schnackenberg, Christine G.
CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (03) : 295 - 300
[30] Discovery of the clinical candidate BMS-816336, an adamantyl acetamide based 11β-hydroxysteroid dehydrogenase type-1 (11β-HSD1) inhibitor
Ye, Xiang-Yang
Chen, Stephanie
Wu, Shung
Yoon, David
Wang, Haixia
Hong, Zhengqiu
Oconnor, Stephen
Li, James
Li, Jun
Walker, Steven
Kennedy, Lawrence
Apedo, Atsu
Nayeem, Akbar
Sheriff, Steven
Morin, Paul
Camac, Daniel
Harrity, Thomas
Zebo, Rachel
Taylor, Joseph
Morgan, Nathan
Ponticiello, Randolph
Golla, Rajasree
Seethala, Ramakrishna
Wang, Mengmeng
Harper, Timothy
Sleczka, Bogdan
He, Bin
Kirby, Mark
DiMarco, John
Scaringe, Raymond
Hanson, Ronald
Guo, Zhiwei
Li, Jianqing
Sun, Jung-Hui
Wong, Michael
Chen, Bang-Chi
Haque, Lauren
Leahy, David
Chan, Collin
Li, Yi-Xin
Zvyaga, Tatyana
Hansen, Lars
Patel, Chirag
Gordon, David
Robl, Jeffrey
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249

← 1 2 3 4 5 →